<div id="readability-page-1"><div> By Nicholas G. Miller <pre></pre> Pfizer posted higher first-quarter revenue but lower profit that was weighed down partially by higher research and development spending. The company posted net income of $2.69 billion, or 47 cents a share, compared with $2.97 billion, or 52 cents a share, the year prior. Adjusted earnings were 75 cents a share. Analysts polled by FactSet expected 72 cents a share. The company said its research and development expenses rose 12% due to higher spending in certain oncology and obesity product candidates. Cost of sales also increased on the unfavorable impact of foreign exchange and the favorable revision of the company's estimate of accrued royalties in the first quarter of 2025. Revenue rose 5% to $14.45 billion. Wall Street expected $13.84 billion. The gains were driven by growth for its Padcev cancer drug, its Eliquis blood thinner, Oncology biosimilars and its Nurtec migraine treatment and were partially offset by declines in COVID-19 product revenues. Demand for Pfizer's Covid-19 pharmaceuticals has fallen precipitously since the peak of the pandemic and the company has been looking for new drugs to make up for the drop-off in sales. As part of its strategy to beef up its pipeline, Pfizer agreed to acquire weight-loss drug startup Metsera last year in a deal that could be worth more than $10 billion. The company reiterated its full-year guidance for revenue of $59.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3 a share. Analysts see full-year sales of $61.38 billion and adjusted earnings of $2.96 a share. <pre></pre> Write to Nicholas G. Miller at nicholas.miller@wsj.com. <pre></pre> (END) Dow Jones Newswires May 05, 2026 07:31 ET (11:31 GMT)Copyright (c) 2026 Dow Jones &amp; Company, Inc.</div></div>

辉瑞

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

辉瑞报告第一季度收入增长 5%，达到 144.5 亿美元，超出华尔街预期。然而，净收入下降至 26.9 亿美元，受到研发费用上涨 12% 的影响。调整后的每股收益为 75 美分，超过分析师预测的 72 美分。公司仍面临 COVID-19 产品销售下滑的挑战，并专注于新药开发，包括收购 Metsera。辉瑞维持全年收入指引在 595 亿美元至 625 亿美元之间，调整后每股收益在 2.80 美元至 3 美元之间

Pfizer 1Q Revenue Rises But Profit Falls Amid Boosted R&D Spending

- 辉瑞第一季度收入增长 5% 至 144.5 亿美元，低于华尔街预期。  
- 净收入为 26.9 亿美元，下降主要因研究开发支出上升 12%。  
- 公司维持全年收入指引在 595 亿至 625 亿美元之间。

MorningStar

Invesco Nasdaq Biotechnology ETF

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

医疗业 ETF - Vanguard

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

Direxion Daily Biotech Top 5 Bull 2X ETF

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

标普全球医疗股指数 ETF - iShares

医疗业 ETF - SPDR

美国制药 ETF - iShares

辉盛研究系统

Metsera

辉瑞第一季度收入增长，但由于研发支出增加，利润下降